Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2019 - 2026)

Mirum Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 57.45% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 57.45% YoY), while the FY2025 annual figure was $5.0 million, up 99.72% from the prior year.
• Other Non-Current Liabilities was $5.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $5.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $140.4 million in Q4 2022 to a low of $7000.0 in Q3 2023.
• Historically, Other Non-Current Liabilities has averaged $22.0 million across 5 years, with a median of $4.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 726305.26% in 2022, then slumped 99.99% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $140.4 million in 2022, then slumped by 97.26% to $3.8 million in 2023, then tumbled by 34.81% to $2.5 million in 2024, then soared by 99.72% to $5.0 million in 2025, then gained by 18.04% to $5.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.9 million (Q1 2026), $5.0 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.